ELITE PHARMACEUTICALS INC /NV/ Quarterly Common Stock, Shares Authorized from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Common Stock, Shares Authorized history and growth rate from Q1 2011 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 1.45B shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 1.45B 0 0% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 1.45B 0 0% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 1.45B 0 0% Mar 31, 2024 10-Q 2024-11-14
Q4 2023 1.45B 0 0% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 1.45B 0 0% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 1.45B 0 0% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 1.45B 0 0% Mar 31, 2023 10-K 2024-07-01
Q4 2022 1.45B 0 0% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 1.45B 0 0% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 1.45B 0 0% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 1.45B 0 0% Mar 31, 2022 10-K 2023-06-29
Q4 2021 1.45B 0 0% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 1.45B 0 0% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 1.45B 0 0% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 1.45B 0 0% Mar 31, 2021 10-K 2022-06-29
Q4 2020 1.45B 0 0% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 1.45B +450M +45.2% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 1.45B +450M +45.2% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 1.45B +450M +45.2% Mar 31, 2020 10-K 2021-06-14
Q4 2019 1.45B +450M +45.2% Dec 31, 2019 10-Q 2020-02-10
Q3 2019 995M 0 0% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 995M 0 0% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 995M 0 0% Mar 31, 2019 10-K 2020-06-30
Q4 2018 995M 0 0% Dec 31, 2018 10-Q 2019-02-11
Q3 2018 995M 0 0% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 995M 0 0% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 995M 0 0% Mar 31, 2018 10-K 2019-06-21
Q4 2017 995M 0 0% Dec 31, 2017 10-Q 2018-02-09
Q3 2017 995M 0 0% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 995M 0 0% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 995M 0 0% Mar 31, 2017 10-K 2018-06-14
Q4 2016 995M 0 0% Dec 31, 2016 10-Q 2017-02-09
Q3 2016 995M 0 0% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 995M 0 0% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 995M +305M +44.2% Mar 31, 2016 10-K 2017-06-14
Q4 2015 995M 0 0% Dec 31, 2015 10-Q 2016-02-09
Q3 2015 995M 0 0% Sep 30, 2015 10-Q/A 2015-12-30
Q2 2015 995M 0 0% Jun 30, 2015 10-Q/A 2015-12-30
Q1 2015 690M 0 0% Mar 31, 2015 10-K 2016-06-15
Q4 2014 995M +305M +44.2% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 995M +305M +44.2% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 995M +305M +44.2% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 690M 0 0% Mar 31, 2014 10-K 2015-06-15
Q4 2013 690M 0 0% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 690M 0 0% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 690M 0 0% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 690M 0 0% Mar 31, 2013 10-K 2014-06-30
Q4 2012 690M +334M +94.1% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 690M +334M +94.1% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 690M +334M +94.1% Jun 30, 2012 10-Q 2012-08-14
Q1 2012 690M 0 0% Mar 31, 2012 10-K 2013-06-21
Q4 2011 356M Dec 31, 2011 10-Q 2012-02-14
Q3 2011 356M Sep 30, 2011 10-Q 2011-11-14
Q2 2011 356M Jun 30, 2011 10-Q/A 2011-08-19
Q1 2011 690M Mar 31, 2011 10-K 2012-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.